Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06556173
PHASE2

Phase 2a Study of VTX3232 in Parkinson's Disease

Sponsor: Zomagen Biosciences Ltd.

View on ClinicalTrials.gov

Summary

This is a study to understand if taking VTX3232 is safe in participants diagnosed with early stage idiopathic Parkinson's Disease (PD). Approximately 10 patients will take VTX3232 Dose A. The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 7-day Pre-Baseline Period, a 28-day Open Label Treatment period (a participant receives active Dose A), and a 14-day Follow-Up Period.

Official title: A Phase 2a, Single Site, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTX3232 in Participants With Early-Stage Parkinson's Disease

Key Details

Gender

All

Age Range

40 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

11

Start Date

2024-08-08

Completion Date

2025-04-04

Last Updated

2026-04-15

Healthy Volunteers

No

Interventions

DRUG

VTX3232

Dose A

Locations (1)

Local Site #840001

New Haven, Connecticut, United States